Skip to content
The Policy VaultThe Policy Vault

Xospata (gilteritinib) — Medica

Acute Myeloid Leukemia

Initial criteria

  • Patient is age ≥ 18 years
  • Disease is FLT3-mutation positive as detected by an approved test

Approval duration

1 year